Life Sciences & Biomedicine Pharmacology & Pharmacy Science & Technology
Aggression is frequently comorbid with neuropsychiatric conditions and is a predictor of worse outcomes, yet current pharmacotherapies are insufficient and have debilitating side effects, precluding broad use. Multiple models of aggression across species suggest that the nicotinic acetylcholine receptor (nAChR) agonist nicotine has anti-aggressive (serenic) properties. Here we demonstrate dose-dependent serenic effects of acute nicotine administration in three distinct mouse strains: C57BL/6, BALB/c, and CD1. While acute nicotine administration (0.25 mg/kg) modestly reduced solitary homecage locomotion, this could not account for nicotine's serenic effects since social encounters eliminated the hypolocomotor effect, and nicotine did not alter social interaction times. Pretreatment with the homomeric (alpha 7 subunit) nAChR antagonist methyllycaconitine (5 mg/kg), but not the heteromeric (beta 2 or beta 4 subunit-containing) nAChR antagonist dihydro-beta-erythroidine (DH beta E, 3 mg/kg), blocked the serenic effects of nicotine. By contrast, pretreatment with DH beta E blocked the effect of acute nicotine administration on locomotion, uncoupling nicotine's serenic and hypolocomotor effects. Finally, the alpha 7 nAChR partial agonist GTS-21 reduced aggression in C57BL/6 mice. These results support the idea that acute nicotine administration has serenic effects and provide evidence for specificity of this effect distinct from effects on locomotion. Furthermore, pharmacological studies suggest that activation of alpha 7 nAChRs underlies the serenic effects of nicotine. Further studies of nAChRs could enhance understanding of the neurobiology of aggression and may lead to the development of novel, more specific treatments for pathological aggression. (C) 2015 Elsevier Inc. All rights reserved.
Modulation of aggressive behavior in mice by nicotinic receptor subtypes
Creators
Alan S. Lewis - Yale University
Yann S. Mineur - Yale University
Philip H. Smith - Yale University
Emma L. M. Cahuzac - Yale University
Marina R. Picciotto - Yale University
Publication Details
Biochemical pharmacology, v 97(4), pp 488-497
Publisher
Elsevier
Number of pages
10
Grant note
MH19961; MH014276; DA14241; MH077681 / National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
R01DA014241 / NATIONAL INSTITUTE ON DRUG ABUSE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); European Commission
R25MH071584 / NATIONAL INSTITUTE OF MENTAL HEALTH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)
Resource Type
Journal article
Language
English
Academic Unit
A.J. Drexel Autism Institute
Web of Science ID
WOS:000363437200016
Scopus ID
2-s2.0-84943350610
Other Identifier
991022030932704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool: